Quantcast

Latest Myeloproliferative disease Stories

2014-08-07 04:21:40

SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose...

2014-07-23 08:31:05

MILWAUKEE, July 23, 2014 /PRNewswire-USNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a Calreticulin (CALR) mutation analysis to identify gene mutations that are found in patients with rare and chronic blood disorders. Detecting a CALR mutation vastly improves the diagnosis of myeloproliferative neoplasms (MPN), a group of diseases that affect blood cell formation. Accurate diagnosis of these disorders provides physicians with...

2014-07-01 04:21:47

-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International, Inc. (Baxter), CTI expects to receive a...

2014-04-10 16:24:24

HILDEN, Germany and VIENNA, April 10, 2014 /PRNewswire/ -- - Reliable diagnostic tools under development for mutations of calreticulin (CALR) are expected to benefit patients with blood disorders known as myeloproliferative neoplasms - QIAGEN acquired exclusive worldwide license for CALR biomarker from CeMM Vienna, whose researchers recently published the discovery in the New England Journal of...

2014-04-08 11:36:36

Melbourne researchers have solved a puzzle as to how an essential blood-making hormone stimulates production of the blood clotting cells known as platelets. Platelets are essential for stopping bleeding and are produced by small fragments breaking off their 'parent' cells, called megakaryocytes. The discovery, made by scientists at the Walter and Eliza Hall Institute, identified how bone marrow cells could become overstimulated and produce too many platelets. In blood diseases such as...

2014-03-28 08:27:04

ASHEVILLE, N.C., March 28, 2014 /PRNewswire/ -- It's hard to imagine heavyweight hematologists publicly squaring off in support of an off-label blood cancer drug. And yet, today, that's exactly what happened in an "Open Letter to the MPN Community of the United States," (http://mpnforum.com/an-open-letter/) published in the April issue of MPNforum Magazine. (www.mpnforum.com) Photo - http://photos.prnewswire.com/prnh/20140328/PH92830-a Photo -...

2014-03-03 04:22:38

- This Trial, Together with PERSIST-1, to Support Registration in the U.S. and Europe - SEATTLE, March 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). The trial is expected to enroll up to 300...

2014-01-30 23:31:18

Following the discovery of the Calreticulin (CALR) mutation, which accounts for the majority of non JAK/MPL mutations in ET and MF patients, Dr. Robert Kralovics sits down with MPN Research Foundation to discuss the discovery. Chicago, IL (PRWEB) January 30, 2014 In December 2013, Dr. Robert Kralovics sat down to discuss the discovery of a genetic mutation that explains the majority of ET and MF for non-JAK and MPL patients. Click here to watch the video. During the late breaking abstract...

2014-01-07 08:30:05

FT. MYERS, Fla., Jan. 7, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology (ASH) last month. Since then, findings...

2013-12-11 12:12:42

A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. State-of-the-art genetic sequencing and analytics tools are being employed in medical research to gain an unprecedented understanding of disease mechanisms and treatments. In the search to improve understanding of disease, two studies...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related